Literature DB >> 14499199

Protective effects of intracerebral adenoviral-mediated GDNF gene transfer in a rat model of Parkinson's disease.

Xianwen Chen1, Weiguo Liu, Yang Guoyuan, Zhenguo Liu, Stuart Smith, Donald B Calne, Shengdi Chen.   

Abstract

This study focuses on the potential protective effects of intracerebral adeno-viral mediated glial cell line derived neurotrophic factor (GDNF) gene transfer in a rat model of Parkinson's disease (PD). Thirty-five SD rats were divided into three groups to receive perinigral injections of recombinant adenovirus encoding GDNF (Ad-GDNF), LacZ (Ad-LacZ) or PBS, respectively. One week later, an intrastriatal injection of 6-hydroxydopamine (6-OHDA) was administered to induce the progressive degeneration of dopaminergic neurons. Immunohistochemistry showed that GDNF treatment prior to neuronal damage could promote survival and morphological recovery of tyrosine hydroxylase (TH)-positive neurons in the midbrain. Approximately 70% of nigral TH-positive cells survived in the Ad-GDNF group, compared to approximately 30% for the Ad-LacZ or PBS control group. Histochemical analysis of monoamine levels in the striatum demonstrated that the dopamine content was higher for the Ad-GDNF group than the control groups. Similarly, Ad-GDNF treated animals showed improved apomorphine-induced rotational behavior. The exogenous GDNF gene was efficiently expressed in the brain as detected by ELISA. This work demonstrates that intracerebral adeno-viral mediated GDNF gene transfer can protect dopaminergic neurons in vivo from 6-OHDA-induced injuries. The approach used in this study could potentially be used therapeutically in patients with PD and further work is required to explore this idea in depth.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14499199     DOI: 10.1016/s1353-8020(03)00097-x

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  7 in total

1.  In vivo transgene expression from an adenoviral vector is altered following a 6-OHDA lesion of the dopamine system.

Authors:  E M Torres; C Monville; P R Lowenstein; M G Castro; S B Dunnett
Journal:  Brain Res Mol Brain Res       Date:  2005-04-18

2.  Virally mediated knock-down of NR2 subunits ipsilateral to the deprived eye blocks ocular dominance plasticity.

Authors:  Zhiping Cao; Lijuan Liu; Marvin Lickey; Aundrea Graves; Tony Pham; Barbara Gordon
Journal:  Exp Brain Res       Date:  2006-08-30       Impact factor: 1.972

3.  Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease using adenoviral vectors Increased yield of dopamine cells is dependent on embryonic donor age.

Authors:  E M Torres; C Monville; P R Lowenstein; M G Castro; S B Dunnett
Journal:  Brain Res Bull       Date:  2005-09-26       Impact factor: 4.077

Review 4.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

5.  Gene delivery to differentiated neurotypic cells with RGD and HIV Tat peptide functionalized polymeric nanoparticles.

Authors:  Jung Soo Suk; Junghae Suh; Kokleong Choy; Samuel K Lai; Jie Fu; Justin Hanes
Journal:  Biomaterials       Date:  2006-10       Impact factor: 12.479

6.  Cell based therapy in Parkinsonism.

Authors:  Johannes Pjm de Munter; Chongsik Lee; Erik Ch Wolters
Journal:  Transl Neurodegener       Date:  2013-06-04       Impact factor: 8.014

Review 7.  Gene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced delivery.

Authors:  Gurwattan S Miranpuri; Lauren Kumbier; Angelica Hinchman; Dominic Schomberg; Anyi Wang; Hope Marshall; Ken Kubota; Chris Ross; Karl Sillay
Journal:  Ann Neurosci       Date:  2012-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.